A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
about
High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis deltaHepatitis delta virus: Making the point from virus isolation up to 2014Direct acting antivirals for the treatment of chronic viral hepatitisHepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an updateDevelopment and evaluation of a baseline-event-anticipation score for hepatitis deltaCirrhosis and its complications: evidence based treatment.Development of mathematical models for the analysis of hepatitis delta virus viral dynamics.Long-term therapy of chronic delta hepatitis with peginterferon alfa.Meta-analysis: antiviral treatment for hepatitis D.Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analysesHepatitis D virus infection, replication and cross-talk with the hepatitis B virus.Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, ChinaHigh prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam.Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection?Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis.Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks.Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysisHepatitis D Virus: A Call to Screening.End points of therapy in chronic hepatitis B.Treatment of delta hepatitis.A rationalized approach to the treatment of patients infected with hepatitis B.Life cycle and pathogenesis of hepatitis D virus: A review.Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression.Hepatitis D virus coinfection and superinfectionTowards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.Hepatitis D and hepatocellular carcinoma.Hepatitis viruses exploitation of host DNA methyltransferases functions.Treatment of Delta Hepatitis: Today and in the Future - A review.Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles.Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells.Noninvasive markers for staging fibrosis in chronic delta hepatitis.Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress.Treatment options for hepatitis delta virus infection.Comparison of Enzyme Immunoassays for Detection of Antibodies to Hepatitis D Virus in Serum.Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy.Hepatitis delta: virological and clinical aspects.A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians.
P2860
Q21132282-CD2D6D8C-375A-4D3C-88AD-02CB3A7E2F44Q26783367-D31ECC88-BCCF-4407-8C91-8CCB02C2568BQ27022216-0807CA33-0C55-4369-8286-4E3BAE2EA9AEQ28284989-A27D9B1D-2224-40B2-8AE4-97ABDD130684Q33414249-C0EAFDBD-58B7-40DA-B5B7-027056826531Q33594931-0397FFAC-42B7-450E-AE3C-85373C6D4598Q33700632-B6603B7A-8954-41E1-B0C7-0FEF89A39DBDQ33904679-97AE6AC0-46A3-4A3D-8009-C893B9FB5A2FQ34138307-5C18BF83-9DC2-4817-913E-2D8981D193AAQ34203972-82B67BBD-42A1-481D-9213-905A5BBF14B8Q34404998-BFA7F45D-00C0-41C3-8A8A-12BED8408375Q34457758-B13E7717-9672-4FBE-A829-6394DD651DC3Q34757956-8621BB40-5988-4A0D-A88E-B6F8649A02D3Q35036020-7173E81D-0A76-4AAB-B500-60955DBA4E17Q35733490-776D5DAB-4576-4367-A047-7F7B7CDA6B75Q35764198-01EB2EED-481D-4863-8E2F-DC7000B071BBQ36037163-B67B9EAB-65EE-4FB7-B3B7-6D974B6729B8Q36428213-49F762DF-DCC0-48EE-98CD-16B998189DD9Q37117293-BD2F1DE8-4998-42D8-9055-74DAAE7B68E8Q37182821-D317B08F-932E-4F3A-BAE4-96DE99E6A4A0Q37688129-7BD4ECFF-601E-4665-ACAE-42FC1A0919BCQ38102778-4B1056CE-B58C-4EC7-846E-E19087564C13Q38168105-290ECACF-6963-4F70-B284-7B0610734881Q38177275-FB229D24-0976-4E9F-9B0C-84861DF91917Q38212153-B33F39FF-F91A-4E15-8C05-236BF10921E7Q38264872-F3E24EF3-B821-4790-BF35-F2DAB8268054Q38351585-7299D57C-C23C-4849-8947-84A2658DDE7DQ38443653-D78872F7-282C-4FD4-A799-33AF881F55D0Q38543225-42AE7B8C-04A9-4FB2-A40E-094DABE63898Q38769975-6434A88F-96BB-444B-85F8-3E84347186EAQ39016102-34D58DC2-3817-4443-B61B-E1B77D773967Q39176720-57537017-24DB-463F-950D-A68087098081Q39215794-B53C215F-0C1E-4E95-9C21-350DF845C6CEQ39281231-21DD3C4A-41F7-4868-B394-AADBF71C0BB9Q39502937-0392DEA5-BFD1-43B6-9594-6C1733F87F56Q39697087-C5A4E828-9FF3-4691-8FA8-248460684FF8Q40004593-FB87A277-BA10-4E85-9A0C-C6CE88450543Q40023495-605D077E-F0A5-4B3A-84C3-0142B42F966FQ40042818-EFBB2DDF-19DF-4CC4-B9FE-6CF28D0C758BQ40438207-0BF0A570-8421-42EE-80CA-44D280FEF159
P2860
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A 28-year study of the course ...... and hepatocellular carcinoma.
@en
A 28-year study of the course ...... and hepatocellular carcinoma.
@nl
type
label
A 28-year study of the course ...... and hepatocellular carcinoma.
@en
A 28-year study of the course ...... and hepatocellular carcinoma.
@nl
prefLabel
A 28-year study of the course ...... and hepatocellular carcinoma.
@en
A 28-year study of the course ...... and hepatocellular carcinoma.
@nl
P2093
P50
P1433
P1476
A 28-year study of the course ...... s and hepatocellular carcinoma
@en
P2093
Ersilio Del Ninno
Guido Ronchi
Massimo Colombo
Roberto de Franchis
P304
P356
10.1053/J.GASTRO.2009.01.052
P407
P577
2009-01-29T00:00:00Z